Donald Trump has rescinded an executive order from President Joe Biden that sought to lower the price of drugs.

Trump’s executive order halts an effort to cap the copayment for generic medications at $2 for Medicare beneficiaries.

An economy expert says short term, senior citizens will continue to carry the high costs of prescription drugs. but President Trump's long-term action could benefit the economy and eventually drive those prices down. 76-year-old Deana Deck is on a fixed income which makes affordable prescriptions a necessity.

President Donald Trump began his second administration with a blitz of policy actions to reorient U.S. government priorities.

President Trump is rolling back Biden healthcare policies, such as expansions to the Affordable Care Act – a move Democrats described as an "attack" on the federal program.

About half of respondents said the nation should spend more on Medicaid and Medicare — a potential challenge for the Trump administration looking to cut costs.

Funding cuts and regulatory changes could radically reduce Medicaid, the largest program providing medical and health-related services to low-income people, as well as Medicare, federal health insurance for people 65 or older, and some under 65 with certain disabilities or conditions.

The Democratic National Committee ( DNC) is going on the offense against President Donald Trump just two days into his second term, blasting the 45th and 47th President over what they say is a plan to follow through on the controversial Project 2025 agenda, including by cutting Social Security, Medicare and Medicaid.

On Day 1 of his second term of office, Trump rescinded Biden's Executive Order 14087, "Lowering Prescription Drug Costs for Americans." Trump's action ha

With a sweep of the pen, President Donald Trump has ended a Biden administration effort to lower the cost of prescription drugs for people on Medicare and Medicaid. Trump's order, signed shortly after his inauguration on Monday,

Trump has reversed some of President Biden’s initiatives, including $2 monthly out-of-pocket cap on some generics and experimental pricing models for gene therapies. But so far the healthcare elements of the Inflation Reduction Act remain unchanged.